Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4323720 | 1.00 | APLNR (0.44) | APLNRPTK2BRD4L3MBTL1ADRA2A | |
| SCHEMBL2609315 | 0.82 | PTK2 (0.38) | APLNRPTK2BRD4L3MBTL1ADRA2A | |
| SCHEMBL1854293 | 0.80 | PTK2 (0.37) | APLNRPTK2BRD4L3MBTL1ADRA2A | |
| SCHEMBL4278366 | 0.80 | PTK2 (0.37) | APLNRPTK2BRD4L3MBTL1ADRA2A | |
| SCHEMBL24501187 | 0.79 | PYGL (0.46) | APLNRBRD4L3MBTL1ADRA2AADRA2B | |
| SCHEMBL29108562 | 0.79 | PYGL (0.46) | APLNRBRD4L3MBTL1ADRA2AADRA2B | |
| SCHEMBL18264342 | 0.79 | TSHR (0.40) | APLNRPTK2BRD4L3MBTL1ADRA2A | |
| SCHEMBL29108209 | 0.79 | PYGL (0.46) | APLNRBRD4L3MBTL1ADRA2AADRA2B | |
| SCHEMBL30640205 | 0.79 | PYGL (0.46) | APLNRBRD4L3MBTL1ADRA2AADRA2B | |
| SCHEMBL30640220 | 0.79 | PYGL (0.46) | APLNRBRD4L3MBTL1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158785-B2 | 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-8158785-B2 | 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-8158785-B2 | 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| CN-101522693-B | Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine deirvatives and their use in therapy | ASTRAZENECA AB | 2012-01-04 | — | — | CN | disclosed |
| EP-2069364-B1 | NOVEL 5, 7-DISUBSTITUTED [1, 3]THIAZOLO [4, 5-D]PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-12-14 | — | — | EP | disclosed |
| EP-2069364-B1 | NOVEL 5, 7-DISUBSTITUTED [1, 3]THIAZOLO [4, 5-D]PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-12-14 | — | — | EP | disclosed |
| CN-101516893-B | 5, 7-disubstituted [1,3] thiazolo [4,5-D ] pyrimidin-2 (3H) -one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2011-11-30 | — | — | CN | disclosed |
| US-7960395-B2 | 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7960395-B2 | 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7960395-B2 | 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20100035899-A1 | 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035899-A1 | 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035899-A1 | 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | US | disclosed |
| CN-101522693-A | Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine deirvatives and their use in therapy | ASTRAZENECA AB (SE) | 2009-09-02 | — | — | CN | disclosed |
| CN-101516893-A | Novel 5, 7-disubstituted [1,3] thiazolo [4, 5-D ] pyrimidin-2 (3H) -one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2009-08-26 | — | — | CN | disclosed |
| US-20080318981-A1 | Novel Compounds 480 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318981-A1 | Novel Compounds 480 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318981-A1 | Novel Compounds 480 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008039139-A1 | NOVEL 5,7-DISUBSTITUTED [1, 3] THIAZOLO [4, 5] PYRIMIDIN-2 (3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039138-A1 | NOVEL 5, 7-DISUBSTITUTED [1, 3 ] THIAZOLO [4, 5-D] PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318981-A1 | Novel Compounds 480 | CX3CR1, CCR2, CXCR3 | APLNR 352/4885PTK2 1206/4885BRD4 763/4885 |
| US-20100035899-A1 | 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | CX3CR1, CCR2, CXCR3 | APLNR 357/4885PTK2 1035/4885BRD4 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.